anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compounds of the formula <FORM:1080148/C2/1> wherein R1 represents a hydrocarbon radical having at most 8 carbon atoms and R2 represents a hydrogen or halogen atom, and their salts with organic or inorganic bases, are prepared by (a) treating a compound of the formula <FORM:1080148/C2/2> wherein X represents a hydrogen atom or a benzyl group, with catalytically activated hydrogen until, depending on the meaning of X substantially the equinolar or double the equinolar amount of hydrogen has been taken up, or (b) treating a compound of the formula <FORM:1080148/C2/3> wherein Y represents a hydrogen atom or a benzyloxycarbonyl group and X represents hydrogen or a benzyl group, not more than one of X and Y being hydrogen, with sodium in liquid ammonia, or (c) treating a compound of the formula <FORM:1080148/C2/4> with at least two equivalents of an alkali metal or alkaline earth metal hydroxide and, if desired, the compound obtained by process (a), (b) or (c) is converted into a salt with an organic or inorganic base.  Starting materials of the Formulae (II), (III) and (IV).-Compounds of the Formula (II) (wherein X is a benzyl group), compounds of the Formula (III) (wherein Y is a benzyloxy-carbonyl group and X is a benzyl group) and compounds of the Formula (IV) are prepared by reacting, in the presence of an acid-binding agent, an N-acylated hydrazobenzene of the formula <FORM:1080148/C2/5> wherein Ac represents a benzyloxycarbonyl or trifluoroacetyl group, with an a -substituted malonic acid benzyl ester chloride of the formula <FORM:1080148/C2/6> and when Ac is a trifluoroacetyl group hydrogenolysing the benzyl ester hydrazide. Compounds of the Formula (II) (wherein X is a hydrogen atom) and compounds of the Formula (III) (wherein X is a hydrogen atom and Y is a benzyloxycarbonyl group) are prepared by reacting a corresponding ethyl or methyl ester chloride instead of the benzyl ester chloride of Formula (VI) with an N-benzyloxycarbonyl hydrazobenzene and partially hydrolysing the ethyl or methyl ester hydrazide obtained with the equivalent amount of potassium or sodium hydroxide. Compounds of the Formula (III) (wherein X is a benzyl group and Y is a hydrogen atom) are prepared by condensing an appropriate malonic acid monobenzyl ester with hydrazobenzene or a dihalogenated hydrazobenzene  N - Benzyloxycarbonyl hydrazobenzene is prepared by reacting hydrazobenzene with chloroformic acid benzyl ester. N-Trifluoroacetyl hydrazobenzene is prepared by reacting hydrazobenzene with trifluoroacetic acid anhydride.  n-Butyl malonic acid benzyl ester chloride is prepared by reacting n-butyl malonic acid monobenzyl ester with thionyl chloride.  Reference has been directed by the Comptroller to the Specification 1,022,010.
The invention relates to a standardized vegetable extract from biomass of in-vitro cultures of Haberlea rhodopensis Friv. (HR) which contains biologically active substances and their primary and secondary metabolites in per cent by weight as follows: organic acids – from 4.0 to 6.0; fatty acids from 0.5 to 1.5, amino acids – from 8.0 to 12.0, sterols – from 0.5 to 1.0, free phenols – from 3.0 to 6.0, sugars – 45 to 55 and polyphenols – from 25.0 to 35.0, wherein the prevailing constituent of the polyphenolic fraction is myconoside – from 70% to 96%, which amounts to 18% to 35% of the entire extract, and to a compound which contains the standardized extract and glycerol, as well as to a method for obtaining the standardized extract. The method according to this invention, owing to its optimally selected steps, specific conditions and parameters such as temperature, time, agitation, light, growth factors and so on, achieves, in addition to maximum productivity by volume of the target substances and myconoside, stable productivity of the vegetable in-vitro cultures, and represents a reliable 24/7 system for the continuous production of HR. The methods eliminates the dependence on natural factors as well as the issues related to the limited availability and the protected status of the rare Haberlea rhodopensis Friv. (HR) populations in wild vegetation environments. The method has been developed so as to provide alternative, renewable and sustainable source of the vegetation material required for the production of the target extract. The obtained extract is standardized by myconoside, which makes it especially valuable due to its protective impact on human health and to the successful utilization of its pharmacological and cosmetic effects, including in functional diets.
Male and female patients at least 18 years of age with untreated Non-small Cell Lung Cancer who have non-incisional biopsy definitive evidence of disease (or from cytology results from a bronchoscope procedure) and who have been previously certified (per centers for Medicare and Medicaid Services requirements) by their physicians will be consented for the study. The study consists of a screening visit, gold-standard 18F-FDG PET/CT imaging followed by the investigational agent 99m Tc-Ec-DG SPECT/CT. The study procedures can be performed within 5-7 days of signing the informed consent. \[To better meet the standard of care at each clinical location, the PET/CT can be performed as part of pre-study procedures on a PET/CT camera previously qualified by the site to meet the standards required for the study. If this occurs, the SPECT/CT must be performed within 45 days of the PET/CT imaging procedures.\] Patients will be seen 24 hours after the 99m Tc-Ec-DG injection for safety. A 21-day follow-up period (after the SPECT/CT image) will allow the investigator to acquire additional imaging, surgical, pathology and treatment documentation. \[An actual patient visit is NOT required at the 21-day follow-up time point.\]
Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. It contains no antimicrobial agents. The nominal pH is 5.0 (4.5 to 7.0). Composition, osmolarity, and ionic concentration are shown below:

0.45% Sodium Chloride Injection, USP contains 4.5 g/L Sodium Chloride, USP (NaCl) and is hypotonic with an osmolarity of 154 mOsmol/L (calc). It contains 77 mEq/L sodium and 77 mEq/L chloride.

0.9% Sodium Chloride Injection, USP contains 9 g/L Sodium Chloride, USP (NaCl) with an osmolarity of 308 mOsmol/L (calc). It contains 154 mEq/L sodium and 154 mEq/L chloride.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2- ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
INTRODUCTION: The efficacy of cancer treatments has links to the intestinal microbiome. Mucositis is a dose-limiting intestinal pro-inflammatory side effect of cancer treatments, that increases the risk of diarrhoea, mucositis, and in severe cases, febrile neutropenia.
METHODS: The effect of cancer treatments on Quality of Life (QoL) was assessed using the FACT C questionnaire that included patient wellbeing and gut adverse symptoms (e.g. diarrhoea). Participants rated faecal samples via the Bristol Stool Chart. In addition, bacterial DNA was extracted from faecal samples, sequenced, and taxonomically examined. The incidence / severity of neutropenia was assessed with white blood cell and neutrophil counts. Circulating SCFAs and plasma lipopolysaccharide (LPS) endotoxin levels were recorded and correlated to intestinal mucositis.
RESULTS: Improvement in bowel function, with reduction in constipation and or diarrhoea or absence of significant disturbance to bowel function was recorded in 85% of the participants. One participant developed febrile neutropenia and two developed bowel toxicity during the study, that was unrelated to the test formulation. No significant changes in microbiota alpha- and beta-diversity at the phylum and species levels respectively from baseline to end of study treatment was observed. None of the participants had raised plasma-endotoxin levels from baseline to the first and subsequent treatment cycles for their cancers. Probiotics in this cohort were deemed safe and tolerable. Significant improvement in emotional QoL scores (p = 0.015) was reported with increased number of chemotherapy cycles. In a related observational study of exceptional responders to chemotherapy, participants were found to have had a high intake of fruits, vegetables, and fibre possibly indicative of a more balanced intestinal microbiota.
CONCLUSION: A multi-strain probiotic formulation was safe and tolerated in this chronically ill cohort that were undergoing oncological treatment. The probiotic formulation alleviated diarrhoea, constipation and maintained stool consistency/frequency during the multiple treatments with chemotherapy and radiotherapy. Intestinal dysbiosis that is characterised by decreased microbial diversity and increased pro-inflammatory species was not observed. Probiotic supplementation may have helped reduce dysbiosis during cancer treatments. These improvements may have been critical with the observation that emotional wellbeing was significantly improved from baseline. Hence albeit that the study had limitations, the probiotic intervention provided adjunctive treatment support to the patients. What is of scientifically plausible interest is that probiotics have a long association historically with human hosts and as such ratify their inclusion offering a significant adjunctive therapeutic potential. Future studies warrant larger sample sizes, control groups and should limit recruitment to a largely homogenous group of patients.
Incomplete recovery following critical illness is a major public health problem in Australia.

Each year around 150,000 Australians are admitted to intensive care (ICU). These critically ill patients require substantial resources and invasive, expensive interventions. Approximately 10% die and many of the remaining patients who survive have delayed and compromised functional recovery. As many as 25% of the ICU survivors who were living at home prior to ICU are unable to return home due to impaired physical function. Globally, the quality of survival following an ICU admission has been identified as one of the largest health challenges for these patients. This study will address the quality of survival and long-term functional recovery for patients who require life support in ICU. These patients account for 62% of the total bed-days in Australian ICUs, with direct care costs of $2 billion per year. The long-term outcomes for these patients are very poor. In my Australian cohort study, 50% of patients who survived hospital had disability
The invention provides a traditional Chinese medicine used for treating cold-dampness heat-type endometritis, and a preparation method thereof. The traditional Chinese medicine is prepared from, root of Chinese Mahonia, herba schizonepetae, Drymaria diandra Blume, Mesona chinensis, Root of Himalayan Prinsepia, Radix Stellariae, Lespedeza bicolor Turcz., Gnaphalium tranzschelii Kirp.G. uliginosum auct. non L, Pistacia weinmannifolia J.Poisson ex Franch.[P.coocinea Collett et Hemsl.], Euonymus fortunei (Turcz.) Hand.Mazz., Cordyceps liangshanensis Zang, Hu et Liu, Radix Vladimiriae, Radix Peucedani, Scytosiphon lomentaria, and Cypripedium japonicum Thunb. The traditional Chinese medicine possesses exact curative effects on cold-dampness heat-type endometritis; toxic and side effect is less; effects are realized quickly; and recurrence is not easily caused.
The disclosure relates to cosmetic hair compositions containing metal-oxide layered pigments. The disclosure also relates to the use of the metal-oxide layered pigments in cosmetic hair compositions. The disclosure also relates to compositions containing film-formers and stabilizers in combination with the metal-oxide layered pigments. The disclosure also relates to cosmetic compositions containing functionalized metal-oxides layered pigments. The disclosure also relates to the use of the functionalized metal-oxide layered pigments in cosmetics such as hair, eyes, lips, skin and nail compositions. The metal-oxide layered pigments are functionalized with ligands which provide improved properties to the pigments in the cosmetics.
BACKGROUND: The aim of this study was to explore the feasibility of ileal ureter replacement and ileocystoplasty for the treatment of bilateral long-segment ureteral strictures combined with bladder contracture.
METHODS: A retrospective review of clinical data from seven patients who underwent bilateral Ileal Ureter Replacement and ileocystoplasty from April 2019 to February 2023 was conducted. The surgeries were performed using open, laparoscopic, and robot-assisted laparoscopic approaches. Baseline characteristics, perioperative, and mid-term results of the patients were collected. Follow-up period of 3-28 months. A detailed description of the technique was reported.
RESULTS: The mean age of the patients was 52.86±6.06 years. The average duration of surgery was 365±28.54 minutes, and the estimated intraoperative blood loss was 357.14±184.06 mL. The mean length of harvested ileum was 37.86±8.40 cm. The preoperative serum creatinine level was 88.02±18.05 μmol/L, postoperative day 1 creatinine level was 90.7±12.93μmol/L, postoperative 3-month creatinine level was 93.77±33.34 μmol/L, and the mean creatinine level at the last follow-up was 94.89±27.89μmol/L. The postoperative bladder capacity was 249.43±32.50 mL on average. The average length of hospital stay was 26.57±15.46 days. No complications of Clavien-Dindo grade 3 or higher were observed. During the follow-up period, no patients experienced deterioration of renal function after surgery.
CONCLUSIONS: Bilateral ileal ureter replacement and ileocystoplasty are effective surgical technique for the treatment of bilateral long-segment ureteral strictures combined with bladder contracture caused by radiation therapy.
OBJECTIVE: Airway surgery is performed for COVID-19 patients who require long-term tracheal intubation and mechanical ventilation. Tracheostomy sometimes causes postoperative complications represented by bleeding at a relatively high rate in COVID-19 patients. As an alternative surgical procedure to tracheostomy, cricotracheostomy may reduce these complications, but few studies have examined its safety.
METHODS: Data were retrospectively collected for sixteen COVID-19 patients (11 underwent tracheostomy, 5 underwent modified cricotracheostomy). In addition to patients' backgrounds and blood test data, the frequency of complications and additional care required for postoperative complications were collected. Statistical analysis was conducted by the univariate analysis of Fischer analysis and Mann-Whitney U test.
RESULTS: Five cases experienced postoperative bleeding, four cases experienced peristomal infection, and one case experienced subcutaneous emphysema in the tracheostomy patients. These complications were not observed in the cricotracheostomy patients. The number of additional cares for postoperative complications was significantly lower in cricotracheostomy than in tracheostomy patients (p < 0.05).
CONCLUSIONS: Modified cricotracheostomy could be a safe procedure in airway surgery for patients with COVID-19 from the point of fewer postoperative complications and additional care. It might be necessary to select the cricotracheostomy depending on patients' background to reduce postoperative complications.
Gene therapy is a promising approach for hereditary deafness. We recently showed that unilateral AAV1-hOTOF gene therapy with dual adeno-associated virus (AAV) serotype 1 carrying human OTOF transgene is safe and associated with functional improvements in patients with autosomal recessive deafness 9 (DFNB9). The protocol was subsequently amended and approved to allow bilateral gene therapy administration. Here we report an interim analysis of the single-arm trial investigating the safety and efficacy of binaural therapy in five pediatric patients with DFNB9. The primary endpoint was dose-limiting toxicity at 6 weeks, and the secondary endpoint included safety (adverse events) and efficacy (auditory function and speech perception). No dose-limiting toxicity or serious adverse event occurred. A total of 36 adverse events occurred. The most common adverse events were increased lymphocyte counts (6 out of 36) and increased cholesterol levels (6 out of 36). All patients had bilateral hearing restoration. The average auditory brainstem response threshold in the right (left) ear was >95 dB (>95 dB) in all patients at baseline, and the average auditory brainstem response threshold in the right (left) ear was restored to 58 dB (58 dB) in patient 1, 75 dB (85 dB) in patient 2, 55 dB (50 dB) in patient 3 at 26 weeks, and 75 dB (78 dB) in patient 4 and 63 dB (63 dB) in patient 5 at 13 weeks. The speech perception and the capability of sound source localization were restored in all five patients. These results provide preliminary insights on the safety and efficacy of binaural AAV gene therapy for hereditary deafness. The trial is ongoing with longer follow-up to confirm the safety and efficacy findings. Chinese Clinical Trial Registry registration: ChiCTR2200063181 .
1,270,765. Immunosuppressive compositions. TAISHO PHARMACEUTICAL CO. Ltd. 6 July, 1970 [14 July, 1969], No. 32596/70. Heading A5B. [Also in Divisions C3 and C4] An immunosuppressive composition comprises a #-1,3-linked polysaccharide, obtained by submerged aerobic culture in a nutrient medium of a strain of microorganism of the family Crepidotaceae or Tricholomaceae, together with a diluent or carrier. The polysaccharide may be in solution in water or saline, or in a solution produced by dissolving the polysaccharide in NaOH solution and neutralising with HCl. To such a neutralised solution may be added penicillin, streptomycin or kanamycin, or the solution may be used in aerosol form with CCl 2 F 2 , propellant.
Tributyltin chloride (TBTC) is known to have effects and mechanisms in various diseases; however, whether TBTC is detrimental to joints and causes osteoarthritis (OA), as well as its underlying mechanism, has not yet been fully elucidated. The present study explored the effects of TBTC on rat chondrocytes, as well as on mouse OA. The toxicity of TBTC toward rat chondrocytes was detected using a lactate dehydrogenase (LDH) leakage assay and cell viability was evaluated using the Cell Counting Kit‑8 assay. The results showed that TBTC decreased the viability of rat chondrocytes and increased the LDH leakage rate in a concentration‑dependent manner. Moreover, compared with in the control group, TBTC increased the expression levels of interleukin (IL)‑1β, IL‑18, matrix metalloproteinase (MMP)‑1, MMP‑13, NLR family pyrin domain containing 3 (NLRP3), caspase‑1, PYD and CARD domain containing, and gasdermin D in chondrocytes. Furthermore, knockdown of NLRP3 reversed the TBTC‑induced increases in LDH leakage and NLRP3 inflammasome‑associated protein levels. In vivo, TBTC exacerbated cartilage tissue damage in mice from the OA group, as evidenced by the attenuation of safranin O staining. In conclusion, TBTC may aggravate OA in mice by promoting chondrocyte damage and inducing pyroptosis through the activation of NLRP3 and caspase‑1 signaling. The present study demonstrated that TBTC can cause significant damage to the articular cartilage; therefore, TBTC contamination should be strictly monitored.
Kyprolis vials contain no antimicrobial preservatives and are intended for single-dose only. The reconstituted solution contains carfilzomib at a concentration of 2 mg/mL.

Read the complete preparation instructions prior to reconstitution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Reconstitution/Preparation Steps:

  1. Remove vial from refrigerator just prior to use.
  2. Calculate the dose (mg/m2) and number of vials of Kyprolis required using the patient's BSA at baseline.
  3. Aseptically reconstitute each Kyprolis vial only with Sterile Water for Injection, USP using the volumes described in Table 6. Use a 21-gauge or larger needle (0.8 mm or smaller external diameter needle) to reconstitute each vial by slowly injecting Sterile Water for Injection, USP through the stopper and directing the Sterile Water for Injection, USP onto the INSIDE WALL OF THE VIAL to minimize foaming. There is no data to support the use of closed system transfer devices with Kyprolis.   


  4. Gently swirl and/or invert the vial slowly for about 1 minute, or until complete dissolution. DO NOT SHAKE to avoid foam generation. If foaming occurs, allow the solution to settle in the vial until foaming subsides (approximately 5 minutes) and the solution is clear.
  5. Visually inspect for particulate matter and discoloration prior to administration. The reconstituted product should be a clear, colorless solution and should not be administered if any discoloration or particulate matter is observed.
  6. Discard any unused portion left in the vial. DO NOT pool unused portions from the vials. DO NOT administer more than one dose from a vial.
  7. Administer Kyprolis directly by intravenous infusion or in a 50 mL to 100 mL intravenous bag containing 5% Dextrose Injection, USP. Do not administer as an intravenous push or bolus.
  8. When administering in an intravenous bag, use a 21-gauge or larger gauge needle (0.8 mm or smaller external diameter needle) to withdraw the calculated dose from the vial and dilute into 50 mL or 100 mL intravenous bag containing only 5% Dextrose Injection, USP (based on the calculated total dose and infusion time).
  9. Flush the intravenous administration line with normal saline or 5% Dextrose Injection, USP immediately before and after Kyprolis administration.
  10. Do not mix Kyprolis with or administer as an infusion with other medicinal products.



The stabilities of reconstituted Kyprolis under various temperature and container conditions are shown in Table 7.
NEW MATERIAL:An immunosuppresive factor having the following properties. Molecular weight; 45,000-65,000, 150,000-200,000 (measured by the gel filtration method) and 31000 [sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis]. Isoelectric point; 4.6-4.8. Eluted with 0.31-0.32 M common salt by the FPLC-Mono Q anion exchange chromatography. Nonadsorbed on immobilied concanavalin A Sepharose and blue Sepharose. Insensitive to (deoxy)ribonuclease, papain and periodic acid and sensitive to trypsin, pronase, etc. Capable of inhibiting antibody production, lymphocytic transformation, cell division and proliferation, etc. USE:An inhibitor for autoimmune diseases, e.g. transplanting rejection, articular rheumatism, etc., allergy, lymphocytic abnormal proliferation, etc. PREPARATION:For example, human T cell leukamic cells are cultivated to give a cultivation supernatant, which is then isolated by suitable combination of methods used for separating proteins.
Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.